In the preoperative neoadjuvant or conversion setting for patients with partially resectable HER2-positive GC, several studies, albeit only phase II, have investigated the efficacy and safety of preoperative trastuzumab with or without PD-1 blockade plus chemotherapy in patients with potentially resectable HER2-positive GC (8–14). The gene discussed is ERBB2; the disease is gastric cancer.